Although prostate speci®c antigen (PSA) is the most useful serum marker for screening, diagnosis and monitoring of prostate cancer, additional biochemical markers have been required for the endocrine management of prostate cancer patients. Chromogranin A is thought to be associated with neuroendocrine differentiation of the prostate cancer cells, and recently it has been suggested that elevated levels of serum chromogranin A correlate with poor prognosis in prostate cancer patients. Although administration of dexamethasone may have favourable effects on patients who had been treated with androgen ablation and had shown progression to an androgenindependent status, the mechanism of dexamethasone therapy remains unknown. Interleukin-6 is known to be suppressed by glucocorticoids, and recent reports showed that interleukin-6 could activate the androgen receptor and stimulate the growth of the prostate cancer cell lines through its receptors in an androgen-independent manner. In the present study, the clinical signi®cance of serum chromogranin A was investigated in untreated patients and the changes in serum interleukin-6 were examined in relation to response to dexamethasone therapy in androgen-independent cases.
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Method
Serum chromogranin A levels were determined in 108 patients with untreated prostate cancer and 66 patients with benign prostatic hyperplasia, and clinicopathological ®ndings and prognosis of prostate cancer patients were examined. In 11 patients who had progressed after androgen ablation and treatment with dexamethasone, the changes in serum PSA, interleukin-6, dehydroepiandrosterone, dehydroepiandrosterone sulfate, androstendione, ACTH and cortisone were measured.
Results
Poorly differentiated cancer had signi®cantly higher levels of serum chromogranin A than well differentiated cancer. Serum chromogranin A values were not a prognostic factor in stage D patients who showed higher levels of serum PSA. In stage D patients who showed lower PSA, however, those with higher chromogranin A levels demonstrated poorer prognosis than those with lower chromogranin A. Of 4 patients who showed 50% or more decline of PSA by dexamethasone therapy, 3 revealed 50% or more decrease in serum interleukin-6. On the contrary, of 7 patients who were poor responders to dexamethasone therapy, only 1 case showed interleukin-6 suppression. Serum levels of adrenal androgens were suppressed by dexamethasone therapy irrespective of the response of PSA.
Conclusion
Measurement of serum chromogranin A in combination with PSA could effectively predict outcomes after endocrine therapy. Suppression of interleukin-6 would be one of the mechanisms of the effects of dexamethasone therapy in androgen-independent prostate cancer.
